Impact of sensor-augmented pump therapy with predictive low-glucose management on hypoglycemia and glycemic control in patients with type 1 diabetes mellitus: 1-year follow-up.

Autor: Gómez AM; Pontificia Universidad Javeriana, Bogotá, Colombia; Hospital Universitario San Ignacio, Division of Endocrinology, Bogotá, Colombia. Electronic address: amgomezm5@gmail.com., Henao DC; Pontificia Universidad Javeriana, Bogotá, Colombia; Hospital Universitario San Ignacio, Division of Endocrinology, Bogotá, Colombia., Taboada LB; Pontificia Universidad Javeriana, Bogotá, Colombia; Hospital Universitario San Ignacio, Division of Endocrinology, Bogotá, Colombia., Leguizamón G; Hospital Universitario San Ignacio, Division of Endocrinology, Bogotá, Colombia., Rondón MA; Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia., Muñoz OM; Hospital Universitario San Ignacio, Department of Internal Medicine, Bogotá, Colombia., García-Jaramillo MA; Faculty of Engineering, Universidad EAN, Bogotá, Colombia., León Vargas FM; Faculty of Mechanical, Electronic and Biomedical Engineering, Universidad Antonio Nariño, Bogotá, Colombia.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2019 Jul - Aug; Vol. 13 (4), pp. 2625-2631. Date of Electronic Publication: 2019 Jul 11.
DOI: 10.1016/j.dsx.2019.07.024
Abstrakt: Aims: To describe real-life experience with sensor-augmented pump therapy with predictive low-glucose management (SAPT-PLGM), in terms of hypoglycemia and glycemic control after one year of follow-up in T1D patients with hypoglycemia as the main indication of therapy.
Methods: Retrospective cohort study under real life conditions. Baseline and one-year follow-up variables of glycemic control, hypoglycemia and glycemic variability were compared.
Results: Fifty patients were included, 31 on prior treatment with SAPT with low-glucose suspend (LGS) feature and 19 on multiple dose insulin injections (MDI). Mean HbA1c decreased in the MDI group (8.24%-7.08%; p = 0.0001). HbA1c change was not significant in the SAPT-LGS group. Area under the curve (AUC) below 70 mg/dl improved in both SAPT-LGS and MDI groups while AUC, %time and events below 54 mg/dl decreased in SAPT-LGS group. Glycemic variability improved in the MDI group. Less patients presented severe hypoglycemia with SAPT-PLGM in both groups, however the change was non-significant.
Conclusions: Under real life conditions, SAPT-PLGM reduced metrics of hypoglycemia in patients previously treaded with MDI and SAPT-LGS without deteriorating glycemic control in SAPT-LGS patients, while improving it in patients treated with MDI.
(Copyright © 2019. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: